PCP
WST icon

Perbak Capital Partners’s West Pharmaceutical WST Stock Holding History

Perbak Capital Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,131
Closed -$1.08M – 326
2025
Q3 		$1.08M Buy
4,131
+1,176
+40% +$286K 0.19% 117
2025
Q2 		$647K Buy
+2,955
New +$632K 0.15% 147

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Perbak Capital Partners's WST Position: Q4 2025 in Review

Perbak Capital Partners sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 4,131 shares — an estimated $1.08M sold.

Perbak Capital Partners first reported a position in WST in Q2 2025 and held it in 2 quarters. The position peaked at $1.08M in Q3 2025. 802 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Perbak Capital Partners reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Perbak Capital Partners sold 4,131 West Pharmaceutical shares in Q4 2025, an estimated $1.08M.
  • Perbak Capital Partners first reported a position in West Pharmaceutical in Q2 2025 and held it in 2 quarters.
  • Perbak Capital Partners's West Pharmaceutical position peaked at $1.08M in Q3 2025.
  • 802 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Perbak Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.